Royalty Pharma Plc Stock Performance
| RPRX Stock | USD 27.71 0.17 0.62% |
Royalty Pharma has a performance score of 4 on a scale of 0 to 100. The company holds a Beta of -0.056, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Royalty Pharma are expected to decrease at a much lower rate. During the bear market, Royalty Pharma is likely to outperform the market. Royalty Pharma Plc right now holds a risk of 1.37%. Please check Royalty Pharma Plc maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to decide if Royalty Pharma Plc will be following its historical price patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Royalty Pharma Plc are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Royalty Pharma is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
Five Day Return (1.63) | Year To Date Return (1.98) | Ten Year Return (37.73) | All Time Return (37.73) |
Forward Dividend Yield 0.0303 | Payout Ratio 0.2139 | Forward Dividend Rate 0.84 | Dividend Date 2024-09-13 | Ex Dividend Date 2024-08-16 |
1 | Disposition of 199098 shares by Riggs Rory B of Royalty Pharma at 27.7867 subject to Rule 16b-3 | 07/05/2024 |
2 | Acquisition by Bassler Bonnie L of 1240 shares of Royalty Pharma at 30.2283 subject to Rule 16b-3 | 07/12/2024 |
3 | Will Royalty Pharma Beat Estimates Again in Its Next Earnings Report | 07/15/2024 |
4 | Exploring Analyst Estimates for Royalty Pharma Q2 Earnings, Beyond Revenue and EPS | 08/05/2024 |
5 | Royalty Pharma PLC Q2 2024 Earnings EPS and Revenue Miss Estimates with 608 Million Revenue | 08/08/2024 |
6 | Royalty Pharma PLC A Strategic SWOT Insight | 08/09/2024 |
7 | Disposition of 2182 shares by Urist Marshall of Royalty Pharma subject to Rule 16b-3 | 08/12/2024 |
8 | Jim Cramer on Royalty Pharma plc Its Been a Bit of a Bust, I Feel Badly | 08/26/2024 |
9 | Royalty Pharma and Ascendis Pharma Enter Into 150 Million Royalty Funding Agreement | 09/03/2024 |
10 | Royalty Pharma plcs Stock Is Rallying But Financials Look Ambiguous Will The Momentum Continue | 09/06/2024 |
| Royalty Pharma dividend paid on 13th of September 2024 | 09/13/2024 |
11 | 3 High-Yield Dividend Stocks Down by More Than percent to Buy Now and Hold at Least a Decade | 09/16/2024 |
12 | Disposition of 150640 shares by Pablo Legorreta of Royalty Pharma subject to Rule 16b-3 | 09/23/2024 |
| Begin Period Cash Flow | 1.7 B |
Royalty |
Royalty Pharma Relative Risk vs. Return Landscape
If you would invest 2,647 in Royalty Pharma Plc on June 27, 2024 and sell it today you would earn a total of 124.00 from holding Royalty Pharma Plc or generate 4.68% return on investment over 90 days. Royalty Pharma Plc is currently generating 0.0831% in daily expected returns and assumes 1.3733% risk (volatility on return distribution) over the 90 days horizon. In different words, 12% of stocks are less volatile than Royalty, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Royalty Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Royalty Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Royalty Pharma Plc, and traders can use it to determine the average amount a Royalty Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0605
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | RPRX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.37 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Royalty Pharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Royalty Pharma by adding it to a well-diversified portfolio.
Royalty Pharma Fundamentals Growth
Royalty Stock prices reflect investors' perceptions of the future prospects and financial health of Royalty Pharma, and Royalty Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Royalty Stock performance.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0345 | ||||
| Profit Margin | 0.30 % | ||||
| Operating Margin | 0.50 % | ||||
| Current Valuation | 17.47 B | ||||
| Shares Outstanding | 448.13 M | ||||
| Price To Earning | 37.70 X | ||||
| Price To Book | 1.92 X | ||||
| Price To Sales | 7.35 X | ||||
| Revenue | 2.35 B | ||||
| Gross Profit | 1.33 B | ||||
| EBITDA | 1.49 B | ||||
| Net Income | 1.13 B | ||||
| Cash And Equivalents | 1.47 B | ||||
| Cash Per Share | 3.34 X | ||||
| Total Debt | 6.14 B | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 2.07 X | ||||
| Book Value Per Share | 14.42 X | ||||
| Cash Flow From Operations | 3.03 B | ||||
| Earnings Per Share | 1.50 X | ||||
| Market Capitalization | 16.44 B | ||||
| Total Asset | 16.38 B | ||||
| Retained Earnings | 2.52 B | ||||
| Working Capital | 1.11 B | ||||
| Current Asset | 10.66 M | ||||
| Current Liabilities | 2.31 M | ||||
About Royalty Pharma Performance
Evaluating Royalty Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Royalty Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Royalty Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.09 | |
| Return On Capital Employed | 0.09 | 0.11 | |
| Return On Assets | 0.07 | 0.08 | |
| Return On Equity | 0.17 | 0.19 |
Things to note about Royalty Pharma Plc performance evaluation
Checking the ongoing alerts about Royalty Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Royalty Pharma Plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Royalty Pharma Plc has a strong financial position based on the latest SEC filings | |
| About 73.0% of the company shares are owned by institutional investors | |
| On 13th of September 2024 Royalty Pharma paid $ 0.21 per share dividend to its current shareholders | |
| Latest headline from fool.com: 3 High-Yield Dividend Stocks Down by More Than percent to Buy Now and Hold at Least a Decade |
- Analyzing Royalty Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Royalty Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Royalty Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Royalty Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Royalty Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Royalty Pharma's stock. These opinions can provide insight into Royalty Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.